Objective: To investigate the effect and safety on the control of fasting and postprandial hyperglycemia by glargine insulin combined with oral hypoglycemic agents (OHA). Methods: 136 T2DM cases with not well controlled hyperglycemia were divided randomly into groups A and B. Groups A and B patients received national glargine and imported glargine respectively in addition to OHA of Metformin and Repaglinide. Blood glucose target rate and the safety, as well as hyperglycemia rate were observed. Results: Levels of FPG, 2hPG and HbA1 c were decreased in post-versus pre-treatment at 2 weeks of treatment. The levels of FPG and 2hPG reached targets at 4 weeks in both groups and HbA1C reached target at 2 months in the schedule of insulin plus OHA. At the end of the study, parameters were improved significantly (all P<0.01) in two groups and the differences between 2 groups showed no statistical significance (P>0.05). Incidence rates of hyperglycemia were 4.2% and 4.6% in groups A and B respectively (P>0.05). Conclusions: (1) Therapeutic effect is similar between imported and national glargine. (2) Combined glargine and Metformin or Repaglinide schedule is effective and safe.